Nuo Therapeutics — Third Quarter 2026 Earnings Summary
Financial Performance:
- Total revenues for the third quarter of 2026 were approximately $1.9 million, an 80% increase year-over-year compared to the same period in 2025.
- Total revenues for the first nine months of 2026 were approximately $4.9 million, a 123% increase year-over-year compared to the same period in 2025.
- Third quarter product revenues increased 5% sequentially versus the second quarter of 2026.
- Aurix wound care revenues increased approximately 17% sequentially in the third quarter, maintaining the same average sequential growth rate observed over the past six quarters.
- Third quarter net operating loss was approximately $374,000, an improvement of approximately $166,000 compared to the third quarter of 2025, but an increase of approximately $208,000 sequentially versus the second quarter.
- The sequential increase in the net operating loss was primarily driven by higher stock-based compensation, credit loss provision expense, and over $100,000 in elevated regulatory costs related to component supply matters.
- As of September 30, 2026, total liabilities were $4,578,709, with total stockholders' deficit at $(1,848,504).
- Cash and cash equivalents stood at $80,941 as of September 30, 2026, down from $548,946 at December 31, 2025.
- Accounts receivable, net, increased to $1,410,322 as of September 30, 2026, from $561,667 at December 31, 2025.
- Deferred revenue totaled $1,332,556 (current: $380,730; long-term: $951,826) as of September 30, 2026.
- Total borrowings under the loan agreement were established at $2,000,000.
Guidance and Future Outlook:
- Final 2027 Medicare OPPS reimbursement rulings indicate the national average reimbursement for G0465 will increase to approximately $2,257, a 7% increase from 2026, with positive pricing actions for Aurix anticipated in 2027.
- Medicare's PFS ruling established a G0465 national average reimbursement of approximately $1,020 in 2027, representing a decrease of approximately 4%.
- Expansion of coverage for G0465 claims for nursing home treatments (Medicare Place of Service 32) is effective January 1, 2027, and is expected to be positive for future growth.
- Management is prioritizing reaching the revenue level required for operational breakeven.
- The company aims to strengthen its capital structure to support the next stage of growth.
Business Segments and Product Lines:
- Aurix wound care revenues achieved the company's highest quarter ever in the hospital setting.
- Since the first quarter of 2026, HOPD (Hospital Outpatient Department) Aurix sales as a percentage of total wound care sales have more than doubled.
- The company received a $250,000 reimbursement fee milestone pursuant to its 2025 distribution agreement with Smith+Nephew.
- The company continues to emphasize growth opportunities in the hospital segment due to strong economics in that setting.
Market and Competitive Landscape:
- The broader wound care market remains unsettled due to dramatic changes to reimbursement economics for skin substitutes/grafts implemented in January.
- There is an observed shift of patients and wound care volumes back to hospital-based settings.
- Management notes that autologous PRP and Aurix are well-positioned for continued long-term attractive growth.
Risks and Challenges:
- The wound care market faces uncertainty regarding reimbursement economics for skin substitutes/grafts.
- Elevated regulatory costs associated with component supply matters have impacted financial results.
- Forward-looking statements regarding growth, reimbursement, and capital structure are subject to known and unknown risks, uncertainties, and factors that may cause actual results to differ materially.
Management Commentary and Tone:
- David Jorden, Chief Executive and Financial Officer, stated that the company remains confident in the long-term growth potential of Aurix and autologous PRP.
- Management highlighted that the funding of secured notes under the loan agreement in several tranches during the year was executed with the priorities of reaching operational breakeven and strengthening the capital structure in mind.
- The tone reflects confidence in the hospital segment's economics and the company's positioning despite broader market unsettledness.
Other Key Points:
- Subsequent to the quarter end, final funding of $325,000 was received under the loan agreement, bringing total borrowings to $2,000,000.
- The company is a commercial-stage medical device company focused on regenerative therapies for chronic wound care, utilizing the Aurix System, a biodynamic hematogel.
- Total assets increased to $2,730,205 as of September 30, 2026, from $1,845,662 at December 31, 2025.
- Property and equipment, net, increased to $704,903 as of September 30, 2026, from $366,315 at December 31, 2025.
- Company
- NUO THERAPEUTICS INC
- Sector
- Healthcare
- Industry
- Medical Devices